Extended-spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae: A Multi-centric Study Across Karnataka

Sridhar PN Rao, Prasad Subba Rama, Vishwanath Gurushanthappa, Radhakrishna Manipura, Krishna Srinivasan

Departments of Microbiology, JJM Medical College, Davangere, Sri Devaraj Urs Medical College, Kolar, Kasturba Medical College, Mangalore, Vijayanagar Institute of Medical Sciences, Bellary, Karnataka, India

Address for correspondence: Mr. Sridhar PN Rao, E-mail: microrao@gmail.com

ABSTRACT

Background: There are sporadic reports on detection of extended-spectrum beta-lactamases (ESBL) producers from Karnataka; hence, this is a first multicentric study across Karnataka state to determine the prevalence of ESBL production among clinical isolates of Escherichia coli and Klebsiella pneumoniae.

Aims and objectives: To determine the prevalence of ESBL producing clinical isolates of E. coli and K. pneumoniae from five geographically distributed centers across Karnataka, to study the susceptibility of ESBL producing isolates to other beta-lactam and beta-lactam-beta-lactamase inhibitors and to demonstrate transferability of plasmids coding for ESBL phenotype.

Materials and Methods: Two hundred isolates of E. coli and K. pneumoniae each were collected from each of the five centers (Bellary, Dharwad, Davangere, Kolar and Mangalore). They were screened for resistance to screening agents (ceftazidime, cefotaxime, ceftriaxone, aztreonam) and positive isolates were confirmed for ESBL production by test described by Clinical and Laboratory Standards Institute. Co-production of ESBL and AmpC beta-lactamase was identified by using amino-phenylboronic acid disk method. Susceptibility of ESBL producers to beta-lactam antibiotics and beta-lactamase inhibitors was performed. Transferability of plasmids was performed by conjugation experiment.

Results: Overall prevalence of ESBL production among E. coli and K. pneumoniae across five centers of the state was 57.5%. ESBL production was found to be 61.4% among E. coli and 46.2% among K. pneumoniae. ESBL production was significantly more among E. coli than K. pneumoniae. Significant variations in distribution of ESBL across the state was observed among E. coli isolates, but not among K. pneumoniae isolates. All ESBL producers demonstrated minimum inhibitory concentration levels ≥2 µg/ml towards cefotaxime, ceftazidime and ceftriaxone.

Conclusion: Overall prevalence of ESBL production among clinical isolates of E. coli and K. pneumoniae across Karnataka state was high. The prevalence of ESBL production was significantly higher with E. coli than K. pneumoniae isolates. Higher rates of resistance to ceftriaxone and cefotaxime than to ceftazidime suggests the possibility of presence of CTX-M type ESBLs. Of all the beta-lactam/beta-lactamase inhibitor combinations tested, cefepime-tazobactam demonstrated highest in-vitro activity against ESBL producers. There was no statistical difference in the transferability of plasmids among E. coli and K. pneumoniae.

Key words: Beta-lactamase, beta-lactamase inhibitor, extended-spectrum beta-lactamases

INTRODUCTION

Treatment of infections caused by Gram-negative bacilli is becoming increasingly difficult because of antibiotic resistance. Various mechanisms such as enzymatic inactivation of antibiotics, altered target sites, decreased porin permeability and active efflux pumps are known to produce drug resistance. One such mechanism is the production of extended-spectrum beta-lactamase (ESBL) enzymes by these bacteria. ESBLs are known to hydrolyze all penicillins, early cephalosporins, oxyimino-cephalosporins and monobactams, but they lack hydrolytic activity on cephamycins and carbapenems. ESBLs are inhibited by beta-lactamase
inhibitors such as clavulanic acid, tazobactam and sulbactam.[3] Treatment failures after instituting beta-lactam antibiotic therapy for infections caused by ESBL producing Gram-negative bacilli have been reported. [2] ESBL producing bacteria have been isolated from healthy subjects, health care workers, food of animal origin, animals, hospital environment, vegetation and sewage.[3–5] As the genes coding for ESBLs are mainly plasmid borne, ESBLs have rapidly disseminated among the bacterial communities, within and across the species. ESBL producing Escherichia coli and Klebsiella pneumoniae have known to cause outbreaks in hospital settings.[6]

Although there are a few reports of ESBL producing bacteria from Karnataka, data from multiple centers across the state is currently lacking. Hence, this is the first multi-centric study that was conducted with the following objectives: (a) To determine the prevalence of ESBL producing clinical isolates of E. coli and K. pneumoniae from five geographically distributed centers across Karnataka (b) to study the susceptibility of ESBL producing isolates to other beta-lactam and beta-lactam-beta-lactamase inhibitors and (c) to demonstrate transferability of plasmids coding for ESBL phenotype.

**MATERIALS AND METHODS**

**Collection of specimen**

Between May 2009 and September 2012, 2000 clinical isolates comprising of 1000 isolates each of E. coli and K. pneumoniae were collected from hospitals attached to Medical Colleges at Davangere (DVG), Kolar (KOL), Mangalore (MNG), Dharwad (DWD) and Bellary (BEL). 200 isolates each of E. coli and K. pneumoniae from each center were randomly collected over a period of 3 years and 3 months. The samples yielding these isolates were as follows: Urine-857, pus-595, sputum-290, blood-92, endotracheal tube-67, throat swab-20, ascitic fluid-19, vaginal swab-14, pleural fluid-13, suction tip-12, rectal swab-8, cervical swab-6, gastric lavage-3 and two each from cerebrospinal fluid and bronchoalveolar lavage samples. Isolation of E. coli and K. pneumoniae from these samples is shown in Table 1. Ethical clearance was obtained from the Institutional Ethical Committee.

**Screening for resistance to oxyimino-cephalosporins**

Isolates were screened for resistance to three oxyimino-cephalosporins: Ceftazidime (30 µg), ceftotaxime (30 µg), ceftriaxone (30 µg) and the monobactam: Aztreonam (30 µg) by disk diffusion test. Isolates that displayed resistance to one or more of these were considered positive for screening test.

**Phenotypic detection of ESBL production**

Presence of ESBL among isolates positive on screening was confirmed by using both ceftazidime/ceftazidime-clavulanic acid (CAZ/CAC) (30/10 µg) and ceftotaxime/ceftotaxime-clavulanic acid (CTX/CEC) (30/10 µg) disks according to phenotypic confirmatory test (PCT). An increase in zone diameter by ≥5 mm around disks with cephalosporin and clavulanic acid versus disks with cephalosporin alone was interpreted as positive as per Clinical and Laboratory Standards Institute (CLSI) 2010 guidelines.[7]

**Detection of ESBL in the presence of AmpC**

Isolates that were positive upon screening but negative by PCT were tested for co-production of ESBL and AmpC enzymes by using amino-phenylboronic acid (APB) disk method as described earlier.[8] Briefly, 400 µg/ml APB acid was added to disks containing ceftotaxime/clavulanic acid (30/10 µg) and ceftotaxime (30 µg). Plain disks with APB acid were used as controls. Interpretation of the test was made as shown in Table 2.

---

**Table 1: Isolation of E. coli and K. pneumoniae from various clinical samples**

| Specimen        | Number of samples n=2000 | E. coli n=1000 | K. pneumoniae n=1000 |
|-----------------|--------------------------|---------------|----------------------|
| Urine           | 857                      | 644           | 243                  |
| Pus             | 595                      | 242           | 353                  |
| Sputum          | 290                      | 61            | 229                  |
| Blood           | 92                       | 35            | 57                   |
| ET tube         | 67                       | 3             | 64                   |
| Throat swab     | 20                       | 4             | 16                   |
| Ascitic fluid   | 19                       | 23            | 6                    |
| Pleural fluid   | 13                       | 5             | 8                    |
| Vaginal swab    | 14                       | 9             | 5                    |
| Suction tip     | 12                       | 2             | 10                   |
| Miscellaneous   | 21                       | 12            | 9                    |

E. coli: Escherichia coli, ET: Endotracheal

**Table 2: Interpretation of amino-phenylboronic acid disk method for co-production of ESBL and AmpC beta-lactamase**

| CTX  | CTX+CLA | CTX+CLA+APB | CTX+APB | Interpretation       |
|------|---------|-------------|---------|----------------------|
| R    | +       | NA          | NA      | ESBL only            |
| R    | −       | +           | +       | AmpC only            |
| R    | −       | +           | −       | ESBL and AmpC        |

CTX: Ceftotaxime, CLA: Clavulanic acid, APB: Amino-phenylboronic acid, R: Resistant, NA: Not applicable, +: ≥5 mm, −: <5 mm, ESBL: Extended-spectrum beta-lactamase
Determination of Minimum inhibitory concentration values

The MIC values for cefoxitin, ceftazidime, cefotaxime and ceftriaxone against isolates identified as ESBL producers were obtained by agar dilution method using a dilution range of 128-0.25 \( \mu \text{g/ml} \) on Mueller Hinton agar. \( K. pneumoniae \) ATCC 700603 and \( E. coli \) ATCC 25922 were used as controls.

Additional susceptibility testing

ESBL producing isolates were further tested for susceptibility to cefepime (30 \( \mu \text{g} \)), cefepime-tazobactam (30/10 \( \mu \text{g} \)), cefepime-clavulanic acid (30/10 \( \mu \text{g} \)) and imipenem (10 \( \mu \text{g} \)) by disk diffusion method.

Transfer of resistance by conjugation

Isolates phenotypically identified as ESBL producers were tested for transferability of the plasmid by conjugation (mating) experiment as described earlier. Test strains and the recipient strain were grown overnight separately in Luria Bertani broth at 37°C. Cultures of test strain and recipient strains were mixed in a separate tube at 1:10 ratio and incubated at 37°C overnight. A volume of 50 \( \mu \text{l} \) of the mixture was placed on Mueller Hinton agar with 2 \( \mu \text{g/ml} \) cefotaxime and 200 \( \mu \text{g/ml} \) sodium azide and incubated at 37°C for up to 48 h. Growth on this medium was interpreted as successful conjugation and such colonies were confirmed for ESBL production by PCT. The recipient strain (\( E. coli \) J53 Az\(^2\)) was kindly provided by George Jacoby.

Statistical methods applied

Using an approximate prevalence rate of 50%, confidence interval of 95%, precision of 5% and using the formula \( n = (Z_{\alpha/2})^2(P(1-P)/D^2) \), a sample size of 385 was calculated. It was rounded off to 400 samples per center including 200 of \( E. coli \) and 200 of \( K. pneumoniae \). The power of study was set at 80%. Categorical data was analyzed by Chi-square test whereas \( z \) test for proportion was used to determine the relationship between groups. \( P \leq 0.05 \) was considered to be statistically significant.

Culture media, antibiotic disks, APB acid, dimethylsulphoxide, ATCC strains were procured from Hi-Media laboratories, Mumbai, India. Pure antibiotic powders for MIC determination were procured from Sigma-Aldrich, Bangalore, India.

RESULTS

Screening test

A total of 1276 isolates were considered as screen positive. Of the 1,000 \( E. coli \) isolates, 740 (74%) were found resistant to one or more the screening agents. Among them 738 (99.7%) were resistant to all the four screening agents. Of the 1,000 \( K. pneumoniae \) isolates, 536 (53.6%) were found resistant to one or more the screening agents. Among them 529 (98.7%) were resistant to all the four screening agents.

Phenotypic detection of ESBL

Of the 1276 isolates that were positive in the screening test, ESBL production was confirmed by PCT in 1076 (84.3%) isolates, which included 614 (61.4%) \( E. coli \) and 462 (46.2%) \( K. pneumoniae \), indicating that the prevalence of ESBL production is 61.4% in \( E. coli \) (ESBL-EC) and 46.2% in \( K. pneumoniae \) (ESBL-KP) across Karnataka. Co-production of ESBL and AmpC beta-lactamase were detected in 58 (2.9%) isolates, which included 56 (5.6%) \( E. coli \) and 2 (0.2%) \( K. pneumoniae \). AmpC production was noted in 35 (3.5%) isolates of \( E. coli \) and 9 (0.9%) isolates of \( K. pneumoniae \). Neither AmpC nor ESBL production could be accounted for cephalosporin resistance in the remaining 35 isolates of \( E. coli \) and 63 isolates of \( K. pneumoniae \).

Distribution of ESBL producers across the state

The distribution of ESBL producing \( E. coli \) and \( K. pneumoniae \) from various centers is as shown in Table 3 and Figure 1. The prevalence of ESBL-EC was noticed to be highest from Bellary center (83.5%) followed by Mangalore and Davangere (63.5% each) and lesser from Dharwad (49.5%) and Kolar (47%) centers. Differences in the prevalence of ESBL-EC across Karnataka was significant \((P < 0.001)\); on the other hand, the prevalence of ESBL-KP across Karnataka was not significant \((P = 0.2)\).
MIC values of ESBL producers

MIC values of ESBL-EC and ESBL-KP isolates to ceftazidime, cefotaxime and ceftriaxone are displayed in Table 4. All the ESBL producers had MIC levels of ≥2 µg/ml to each of the third generation cephalosporins tested, thus confirming resistance. At the concentration of ≥128 µg/ml of ceftriaxone and cefotaxime, 493 (80.3%) and 486 (79.1%) isolates of ESBL-EC respectively were resistant; however, at a similar concentration of ceftazidime only 228 (37.1%) isolates of ESBL-EC showed resistance. These differences in resistance pattern at the concentration ≥128 µg/ml were statistically significant (P < 0.001). This observation was also true with ESBL-KP. At the concentration of ≥128 µg/ml of ceftriaxone and cefotaxime, 382 (82.7%) and 343 (74.2%) isolates of ESBL-KP respectively were resistant; however, at a similar concentration of ceftazidime only 253 (54.8%) of ESBL-KP showed resistance.

Resistance pattern to other beta-lactams, beta-lactam-beta-lactamase inhibitors

Table 5 presents resistance pattern of the ESBL producing isolates to certain beta-lactam antibiotics other than those used for testing and beta-lactam/beta-lactamase inhibitors.

![Figure 1: Distribution of extended-spectrum beta-lactamase producers from five centers across Karnataka](image)

| MIC range (µg/ml) | Ceftriaxone n (%) | Cefotaxime n (%) | Ceftazidime n (%) |
|-------------------|-------------------|-----------------|-------------------|
|                   | EC                | KP              | EC                | KP              | EC                | KP              |
| ≥128              | 493 (80.3)        | 382 (82.7)      | 486 (79.1)        | 343 (74.2)      | 228 (37.1)        | 253 (54.8)      |
| 16-64             | 119 (19.4)        | 70 (15.1)       | 123 (20)          | 102 (22.1)      | 331 (53.9)        | 176 (38.4)      |
| 2-8               | 2 (0.3)           | 10 (2.2)        | 5 (0.8)           | 17 (3.7)        | 55 (8.9)          | 33 (7.2)        |

Table 4: MIC values of ESBL producers to ceftazidime, cefotaxime and ceftriaxone

EC: Escherichia coli; KP: Klebsiella pneumoniae; MIC: Minimum inhibitory concentration; ESBL: Extended-spectrum beta-lactamase
inhibitor combinations. Resistance to the combination of cefotaxime and clavulanic acid was almost the same in case of ESBL-EC (53.4%) and ESBL-KP (49.6%); however, 32.2% ESBL-KP and 9.1% of ESBL-EC were resistant to the combination of ceftazidime and clavulanic acid. This difference was found to be significant ($P < 0.001$). It was observed that 89.1% of ESBL-EC and 79.9% of ESBL-KP were resistant to cefepime. This resistance was reduced considerably (from 89.1% to 2.9%) when cefepime was combined with tazobactam or clavulanic acid. Of all the combinations of beta-lactam/beta-lactamase inhibitor tested, cefepime-tazobactam had the least resistance. Cefoxitin resistance was observed both in ESBL-EC (38.6%) and ESBL-KP (48.5%). Only 2 (0.3%) ESBL-EC and 11 (2.4%) ESBL-KP were found resistant to imipenem.

**Plasmid transfer by conjugation**

Plasmid mediated resistance transfer was successfully demonstrated in 362/614 (59%) isolates of ESBL-EC and 249/462 (53.9%) isolates of ESBL-KP.

**DISCUSSION**

In a multi-centric study conducted as part of India SENTRY surveillance, the prevalence of ESBL production was reported to be 84%. Here we found that 61.4% of *E. coli* and 46.2% of *K. pneumoniae* isolates collected across five centers of Karnataka were ESBL producers. The prevalence of ESBL-EC was significantly more ($P < 0.001$) than ESBL-KP.

ESBL production among *Enterobacteriaceae* members vary widely from region to region and sometimes within the state. We found that the prevalence of ESBL producing bacteria varied across Karnataka with respect to *E. coli* but not with *K. pneumoniae*. In the case of *E. coli* it was highest at Bellary (87.5%) and lowest at Kolar (52.5%). However, it was almost the same with respect to *K. pneumoniae* expect from Dharwad. These differences could be due to varied degree exposure of these organisms to beta-lactam antibiotics or due to varied transferability of plasmids in nature among them. However, our plasmid transmission studies conducted in the laboratory did not reveal a significant difference ($P = 0.09$) in the transferability of plasmid in ESBL-EC and ESBL-KP.

Earlier studies from Karnataka found that the detection rates of ESBL-EC has varied from 23.6% (Raichur) to 86.7% (Shimoga). The detection rates of ESBL-KP from different studies across Karnataka has been reported to vary from 9.6% (Bangalore) to 81.8% (Mangalore). Reports of ESBL detection among clinical isolates of *E. coli* range between 20% and 80.6% and those among *K. pneumoniae* ranges between 20% and 86.7% across the country; these findings are summarized in Table 6. The variation in the detection rates within and across the states could be due to the differences in the methodology used in these studies. We made our study stringent by using four beta-lactam antibiotics for screening and two beta-lactam and beta-lactamase inhibitor combination disks for confirmation of ESBL as per the CLSI guidelines, thus, bringing uniformity in testing.

Co-production of AmpC beta-lactamase and ESBL among the isolates in this study has been only minimal (2.9%), but was observed to be higher among *E. coli* (5.6%) isolates than *K. pneumoniae* (0.2%) isolates. Our findings contrasts with that reported from Bangalore and Manipal. The study from Manipal reported a co-production rate of 58.5% among *E. coli*; a study from Bangalore reported a co-production rate of 30.1% for *E. coli* and 30.3% for *Klebsiella* spp. These variations could be due to differences in the methodologies adopted.

In the present study reported, none of the ESBL producing bacteria had MIC of $< 2 \mu g/ml$ towards ceftazidime, cefotaxime or ceftriaxone. The ESBL producers exhibited significantly higher MIC levels ($\geq 128 \mu g/ml$) to cefotaxime and ceftriaxone than to ceftazidime. This difference suggests

### Table 5: Antibiotic resistance to other beta-lactam antibiotics and beta-lactamase inhibitors

| Antibiotics tested | *Escherichia coli* n (%) | *Klebsiella pneumoniae* n (%) |
|--------------------|--------------------------|-----------------------------|
| Cefotaxime-clavulanic acid | 328 (93.4) | 229 (94.6) |
| Ceftazidime-clavulanic acid | 56 (9.2) | 143 (32.2) |
| Cefepime | 547 (89.2) | 369 (79.9) |
| Cefepime-clavulanic acid | 53 (8.6) | 94 (20.3) |
| Cefepime-tazobactam | 18 (2.9) | 48 (10.4) |
| Cefoxitin | 237 (38.6) | 224 (48.8) |
| Imipenem | 2 (0.3) | 22 (4.4) |

### Table 6: Reports of ESBL production in EC and KP across the country

| Location    | ESBL-EC % | ESBL-KP % | Reference |
|-------------|-----------|-----------|-----------|
| Mumbai      | 20        | 20        | Vaidya et al. |
| Chandigarh  | 70        | 60        | Sharma et al. |
| Pondicherry | 60.8      | 39.2      | Mohamudha Parveen et al. |
| Amritsar    | 46.4      | 52.3      | Kaur and Aggarwal et al. |
| Salem       | 79.5      | 50        | Priyadharshini et al. |
| Guwahati    | 43        | 67        | Sarma et al. |
| Ujjain      | 69        | 41        | Pathak et al. |
| Indore      | 80.6      | 86.7      | Chithnis et al. |

EC: *Escherichia coli*, KP: *Klebsiella pneumoniae*, ESBL-EC: ESBL producing *E. coli*, ESBL-KP: ESBL producing *K. pneumoniae*
the presence of CTX-M type ESBLs that hydrolyse cefotaxime and ceftriaxone more efficiently than ceftazidime.[25]

Cefoxitin, which is a cephamycin is not hydrolyzed by ESBLs, but in our study we have observed resistance in both *E. coli* (38.5%) and *K. pneumoniae* (48.5%) isolates. Earlier studies have suggested that cefoxitin resistance could be due to altered membrane porins.[26] Cefepime resistance among the ESBL producers was also found to be high among both *E. coli* (89.1%) and *K. pneumoniae* (79.9%). Similarly, high resistance to the tune 97.4% was observed among ESBL-EC isolates from Bangalore.[23] Resistance to cefepime could be attributed to the high prevalence of CTX-M type ESBLs in these isolates, some of which are capable of hydrolyzing cefepime.[27] Cefepime-tazobactam combination was found to be more effective than cefepime-clavulanic acid combination against ESBL producing isolates.

Although all ESBL producing isolates were resistant to cefazidime and cefotaxime in the screening test, addition of clavulanic acid did not render all the isolates susceptible to the cephalosporins. Cefazidime-clavulanic acid combination had better inhibitory effect on ESBL-EC and ESBL-KP than cefotaxime-clavulanic acid. This difference in susceptibilities also highlights the possible presence of CTX-M type enzymes in these isolates. ESBLs have no hydrolytic activity on imipenem, but resistance was noted in two *E. coli* and 11 *K. pneumoniae* isolates. Presence of other beta-lactamases or alterations in porin channels might account for this resistance.[28] As the co-resistance to imipenem in ESBL producers is low, it continues to be effective in treating diseases caused by them.

Presence of ESBL genes on plasmids was demonstrated successfully by mating experiment in 56.8% isolates. *E. coli* isolates were found to readily transfer the plasmids than *K. pneumoniae*, although this observation was statistically not significant. Presence of bla gene on non-transmissible plasmids can account for failure in conjugation experiments. Recently, a study was conducted at Mumbai, which evaluated horizontal transfer rates of ESBL carrying plasmids by conjugation. The author reported transfer of resistance under laboratory and environmental conditions at a frequency of $3\times 10^{-3}$, which is high.[19] The promiscuity of the isolates in transferring the plasmid containing bla gene does not seem to be very high in our study.

**CONCLUSION**

Prevalence of ESBL production among *E. coli* was 61.4% and 46.2% among *K. pneumoniae* across Karnataka state. The prevalence of ESBL production was significantly higher with *E. coli* than *K. pneumoniae* isolates. There was significant variation in the distribution of ESBL-EC across Karnataka, but not so with ESBL-KP. Isolates that co-produced ESBL and AmpC enzymes were marginally low in both the species. All ESBL producers had MIC levels $\geq 2 \mu g/ml$ toward cefotaxime, ceftriaxone and ceftazidime. High level resistance was more apparent with cefotaxime and ceftriaxone than with ceftazidime. Susceptibility pattern indicates possible presence of CTX-M type ESBLs amongst ESBL producers. Cefepime-tazobactam has highest *in-vitro* activity against ESBL producers than cefotaxime-clavulanic acid, ceftazidime-clavulanic acid or cefepime-clavulanic acid. This study, which has shown conjugation rate of 58.8% indicates that conjugation is perhaps only moderate but not rampant.

**Strength and weakness of the study**

This is the first study to undertake a multi-centric study on prevalence of ESBL-EC and ESBL-KP across Karnataka, which has also demonstrated unusually high levels of resistance to cefotaxin and cefepime. A state-wide surveillance not only reveals the prevalence and the extent of distribution of ESBLs among *E. coli* and *K. pneumoniae* but also helps in monitoring degree of resistances to beta-lactam antibiotics and beta-lactam inhibitor combinations. Although other combinations of beta-lactams and beta-lactamase inhibitors were tested, other antimicrobials like aminoglycosides, fluoroquinolones were not tested since it was beyond the scope of this study. Genotypic study on beta-lactamase gene using polymerase chain reaction would have given better picture on the prevalent ESBL type. Even though, samples were from five geographically distinct location, the results cannot be applied to the entire state.

**ACKNOWLEDGMENTS**

Dr. RD Kulkarni, professor, Department of Microbiology, SDM CMSH, Dharwad, Dr. Beena PM, professor, Department of Microbiology, SDUM, Kolar and Dr. George Jacoby, Lahey Clinic, Massachusetts, USA.

**REFERENCES**

1. Giske CG, Sundsfjord AS, Kahlmeter G, Woodford N, Nordmann P, Paterson DL, et al. Redefining extended-spectrum beta-lactamases: Balancing science and clinical need. *J Antimicrob Chemother* 2009;63:1-4.
2. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum beta-lactamase. *J Antimicrob Chemother* 1996;37:203-4.
3. Calbo E, Freixas N, Xercavins M, Riera M, Nicolas C, Monistrol O, et al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing
Rao, et al.: Prevalence of ESBL producing E. coli and K. pneumoniae across Karnataka isolates in a tertiary care hospital from India.

13. Eshwarappa M, Dosegowda R, Aprameya IV, Khan MW, Kumar PS, Ali S, Khan I. Prevalence of extended spectrum beta-lactamases (ESBLs) in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clin Microbiol Infect 2010;16:33-8.

5. Shaheen BW, Nayak R, Foley SL, Kweon O, Deck J, Park M, et al. Molecular characterization of resistance to extended-spectrum cephalosporins in clinical Escherichia coli isolates from companion animals in the United States. Antimicrob Agents Chemother 2011;55:5660-75.

6. Webster DP, Young BC, Morton D, Collyer D, Bathebok LR, Turton JF, et al. Impact of a clonal outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by Klebsiella pneumoniae and Escherichia coli. An 11 year experience in Oxfordshire, UK. J Antimicrob Chemother 2011;66:2126-35.

9. Park YJ, Park SY, Oh EJ, Park JH, Lee KY, Woo GJ, et al. Detection of ESBL-producing Enterobacteriaceae and antibiotic co-resistance. Indian J Med Res 2010;132:332-6.

10. Manoharan A, Premalatha K, Chatterjee S, Mathai D, SARI Study Group. Correlation of TEM, SHV and CTX-M extended-spectrum beta-lactamases among Enterobacteriaceae with their antimicrobial susceptibility. Indian J Med Microbiol 2011;29:161-4.

11. Harwalkar A, Sataraddi J, Gupta S, Yogandar R, Rao A, Srivasa H. The detection of ESBL-producing Enterobacteriaceae in patients with symptomatic urinary tract infections using different diffusion methods in a rural setting. J Infect Public Health 2013;6:108-14.

12. Bhat PV, Sarkar A. Emergence and control of multidrug resistant organisms in small cities in India: A wake up call. Indian J Med Sci 2011;65:337-43.

13. Eshwarappa M, Dosegowda R, Aparameya IV, Khan MW, Kumar PS, Kempengowda P. Clinicopathological profile of urinary tract infection in south India. Indian J Nephrol 2011;21:30-6.

14. Kamath S, Mallaya S, Shenoy N. Nosocomial infections in neonatal intensive care units: Profile, risk factor assessment and antibioticogram. Indian J Pediatr 2010;77:37-59.

15. Vaidya VK. Horizontal transfer of antimicrobial resistance by extended-spectrum beta-lactamase-producing enterobacteriaceae. J Lab Physicians 2011;3:37-42.

16. Sharma J, Sharma M, Rakesh P. Detection of TEM and SHV genes in Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital from India. Indian J Med Res 2010;132:332-6.

17. Mohanadha Parveen R, Manivannan S, Harish BN, Parija SC. Study of CTX-M type of extended spectrum beta-lactamase among nosocomial isolates of Escherichia coli and Klebsiella pneumoniae in South India. Indian J Microbiol 2012;52:35-40.

18. Kaur M, Aggarwal A. Occurrence of the CTX-M, SHV and the TEM genes among the extended spectrum beta-lactamase producing isolates of enterobacteriaceae in a Tertiary Care Hospital of North India. J Clin Diagn Res 2013;7:642-5.

19. Priyadarsini RI, Kavitha A, Rajan R, Mathavi S, Rajesh KR. Prevalence of blaCTX-M extended-spectrum beta-lactamase gene in enterobacteriaceae from critical care patients. J Lab Physicians 2011;3:80-3.

20. Sarma JB, Bhattacharya PK, Kalita D, Rajbangshi M. Multidrug-resistant Enterobacteriaceae including metallo-beta-lactamase producers are predominant pathogens of healthcare-associated infections in an Indian teaching hospital. Indian J Med Microbiol 2011;29:22-7.

21. Pathak A, Marathi Y, Kekre V, Mahadik K, Macaden R, Lumborg CS. High prevalence of extended-spectrum beta-lactamase-producing pathogens: Results of a surveillance study in two hospitals in Ujjain, India. Infect Drug Resist 2012;5:65-73.

22. Chitnis S, Kata P, Heman V, Chitnis DS. Augmentation in zone of inhibition of cefoperazone/cefoperazone+ sulbactum compares well with the clinical laboratory standard institute standard extended spectrum beta-lactamase detection method as well as the polymerase chain reaction method. Curr Drug Saf 2011;6:155-8.

23. Radhesh SM, Nagarathnamma T. Extended spectrum beta-lactamase producing Enterobacteriaceae and antibiotic co-resistance. Indian J Med Res 2011;133:116-8.

24. Shobha KL, Ramachandra I, Rao G, Majumder S, Rao SP. Extended spectrum beta-lactamases (ESBL) in gram negative bacilli at a Tertiary Care Hospital. J Clin Diagn Res 2009;3:1307-12.

25. Tsouvelekis LS, Tzelepí E, Tassios PT, Legakis NJ. CTX-M-type beta-lactamas: An emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000;14:137-42.

26. Ananthan S, Subha A. Cefoxitin resistance mediated by loss of a porin from a porin-deficient isolate of Klebsiella pneumoniae. J Hosp Infect 2005;61:269-75.

27. Yu WL, Pfaller MA, Winokur PL, Jones RN. Cefepime MIC as a predictor of clinical failure of therapy. Int J Antimicrob Agents 2008;32:522-4.

28. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodriguez MC, Velasco M, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008;32:534-7.

**How to cite this article:** Rao SP, Rama PS, Gurushanthappa V, Manipura R, Srinivasan K. Extended-spectrum beta-lactamases producing *Escherichia coli* and *Klebsiella pneumoniae*: A Multi-centric Study Across Karnataka. J Lab Physicians 2014;6:7-13.

**Source of Support:** Nil. **Conflict of Interest:** None declared.